Skip to main content

Advertisement

Table 3 SIR for subsequent hemorrhagic stroke of patients with IMD

From: Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden

  Follow-up interval (years)
  <1 1-5 5-10 > = 10 All
Immune-mediated diseases O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Addison´s disease 2 2.70 0.25 9.94 2 0.64 0.06 2.34 1 0.42 0.00 2.41 1 0.55 0.00 3.17 6 0.74 0.27 1.63
Amyotrophic lateral sclerosis 1 0.47 0.00 2.68 2 1.30 0.12 4.78 1 1.82 0.00 10.42 0     4 0.89 0.23 2.30
Ankylosing spondylitis 6 8.11 2.92 17.76 15 3.43 1.92 5.68 7 1.66 0.66 3.44 14 2.28 1.24 3.84 42 2.72 1.96 3.67
Autoimmune hemolytic anemia 1 3.13 0.00 17.91 4 2.96 0.77 7.66 1 1.15 0.00 6.59 2 2.99 0.28 10.98 8 2.49 1.06 4.93
Behcet´s disease 1 33.33 0.01 191.08 0     0     0     1 1.67 0.00 9.55
Celiac disease 2 3.57 0.34 13.13 6 2.08 0.75 4.56 7 2.69 1.07 5.58 8 2.65 1.13 5.25 23 2.54 1.61 3.81
Chorea minor 0     0     0     0     0    
Crohn disease 5 1.47 0.46 3.46 47 2.60 1.91 3.46 19 1.19 0.72 1.87 24 1.57 1.00 2.34 95 1.80 1.46 2.21
Diabetes mellitus type I 0     2 2.50 0.24 9.19 1 1.11 0.00 6.37 2 1.01 0.09 3.70 5 1.32 0.42 3.10
Discoid lupus erythematosus 1 11.11 0.00 63.69 1 2.33 0.00 13.33 0     0     2 1.87 0.18 6.87
Grave´s disease 8 1.53 0.65 3.02 58 1.77 1.35 2.29 48 1.61 1.18 2.13 41 1.48 1.06 2.02 155 1.62 1.38 1.90
Hashimoto´s thyroiditis 4 1.47 0.38 3.79 27 2.01 1.32 2.93 19 2.10 1.26 3.29 11 1.37 0.68 2.46 61 1.84 1.40 2.36
Immune thrombocytopenic purpura 8 8.60 3.67 17.03 12 2.81 1.45 4.92 6 2.18 0.79 4.78 2 1.23 0.12 4.54 28 2.93 1.94 4.23
Localized scleroderma 0     1 0.93 0.00 5.36 1 0.85 0.00 4.90 6 4.32 1.55 9.46 8 2.11 0.90 4.17
Lupoid hepatitis 0     0     0     0     0    
Multiple sclerosis 4 1.82 0.47 4.70 15 1.36 0.76 2.25 9 1.09 0.49 2.08 6 0.94 0.34 2.06 34 1.22 0.84 1.71
Myasthenia gravis 1 1.22 0.00 6.99 8 2.09 0.89 4.14 6 2.17 0.78 4.76 0     15 1.62 0.90 2.68
Pernicious anemia 4 2.15 0.56 5.56 18 1.67 0.99 2.65 13 1.52 0.81 2.61 7 0.99 0.39 2.06 42 1.49 1.07 2.01
Polyarteritis nodosa 2 5.41 0.51 19.88 0 0.00 0.54 2.19 3 1.91 0.36 5.66 0     5 1.00 0.31 2.34
Polymyalgia rheumatica 21 2.06 1.28 3.16 78 1.42 1.12 1.77 65 1.67 1.29 2.13 40 1.49 1.06 2.03 204 1.56 1.35 1.79
Polymyositis/ dermatomyositis 1 2.63 0.00 15.08 3 1.95 0.37 5.77 1 1.18 0.00 6.74 1 2.08 0.00 11.94 6 1.85 0.66 4.04
Primary biliary cirrhosis 1 2.08 0.00 11.94 3 1.76 0.33 5.22 2 2.17 0.20 7.99 0     6 1.87 0.67 4.10
Psoriasis 9 2.88 1.31 5.50 32 1.83 1.25 2.59 23 1.51 0.95 2.26 21 1.32 0.81 2.02 85 1.64 1.31 2.03
Reiter´s disease 0     1 2.94 0.00 16.86 1 2.56 0.00 14.70 0     2 1.42 0.13 5.22
Rheumatic fever 1 7.69 0.00 44.09 0     0     1 1.72 0.00 9.88 2 1.04 0.10 3.81
Rheumatoid arthritis 65 3.27 2.52 4.17 191 2.03 1.76 2.34 109 1.92 1.57 2.31 61 1.78 1.36 2.29 426 2.08 1.89 2.29
Sarcoidosis 3 2.48 0.47 7.34 12 1.87 0.96 3.28 14 2.26 1.23 3.80 6 0.79 0.28 1.73 35 1.64 1.14 2.28
Sjögren´s syndrome 0     3 1.35 0.25 4.00 2 1.03 0.10 3.77 0     5 0.81 0.26 1.90
Systemic lupus erythematosus 9 8.65 3.92 16.50 13 2.89 1.53 4.95 4 1.17 0.31 3.03 6 1.91 0.69 4.19 32 2.65 1.81 3.74
Systemic sclerosis 2 3.17 0.30 11.67 5 2.67 0.84 6.29 3 2.73 0.51 8.07 2 3.45 0.33 12.68 12 2.87 1.48 5.03
Ulcerative colitis 7 1.45 0.57 3.00 40 1.45 1.03 1.97 28 1.21 0.80 1.74 33 1.44 0.99 2.02 108 1.37 1.13 1.66
Wegener´s granulomatosis 6 5.83 2.10 12.76 3 0.90 0.17 2.67 2 1.08 0.10 3.95 0     11 1.47 0.73 2.63
All 175 2.65 2.27 3.08 602 1.83 1.69 1.98 396 1.63 1.47 1.80 295 1.47 1.31 1.65 1468 1.75 1.66 1.84
  1. O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.
  2. Bold type: 95% CI does not include 1.00.
  3. Adjusted for age, period, socioeconomic status, region of residence, hospitalization of chronic lower respiratory diseases, obesity, alcoholism, hypertension, diabetes, atrial fibrillation, heart failure, renal disease, sepsis, and coronary heart disease.